• BioAI and Arbele have partnered to develop AI-powered diagnostics for colorectal cancer, using BioAI’s PredictX platform and Arbele’s clinical trial data.
  • The collaboration aims to enhance biomarker screening for Arbele’s immunotherapy, improving patient selection and treatment outcomes for gastrointestinal cancers.

BioAI, a rising player in biotech focused on AI-driven biomarker discovery and diagnostics, has announced a strategic collaboration with Arbele, a biopharma firm specializing in immunotherapy for gastrointestinal cancers.

The partnership will harness BioAI’s PredictX platform to develop AI-powered models from Arbele’s clinical trial data, with an emphasis on colorectal cancer (CRC) biomarker screening. This collaboration aims to create a companion diagnostic test for Arbele’s drug assets, improving patient selection through advanced AI technology.

"By joining forces with Arbele, we are excited to apply our novel AI platform and expertise to accelerate the development of innovative treatment options for gastrointestinal cancers," said Thomas Colarusso, CEO of BioAI.
"This partnership underscores our commitment to revolutionizing personalized medicine through cutting-edge machine learning."

Arbele's CEO and Founder, Dr. John Luk, stated that BioAI's machine-learning capabilities provide a transformative approach to biomarker identification and patient stratification. He emphasized that the collaboration is a crucial step toward improving outcomes for patients with high-mortality cancers.

The first phase of the partnership will center on creating a prototype machine learning classifier to measure CDH17 expression patterns in colorectal cancer (CRC) samples, leveraging a combination of H&E (hematoxylin and eosin) and IHC (immunohistochemistry) stained images. This effort aims to streamline and enhance the pathological evaluation of treatment response biomarkers, improving patient selection for Arbele’s targeted therapeutic programs.

Both companies anticipate that this collaboration will drive future innovations in precision medicine, with a focus on improving outcomes for patients with gastrointestinal cancers.

Edited by Harshajit Sarmah

ALSO READ:

Autonom8 Partners with Matrix to Automate End-to-End Physical Audits
With Autonom8’s Audit platform, Matrix automates the entire audit workflow—from task assignment to real-time tracking and comprehensive report generation.
NewzchainHarshajit Sarmah